Antifibrinolytic therapy with tranexamic acid in cardiac operations

K. Matsuzaki, K. Matsui, Yoshihisa Tanoue, I. Nagano, N. Haraguchi, Hideki Tatewaki

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

To demonstrate its antifibrinolytic effects and establish an effective regimen of tranexamic acid for hemostasis, the authors measured α2-plasmin inhibitor—plasmin complexes, thrombin—antithrombin III complexes and postoperative blood loss in three groups undergoing different regimens during cardiac operations. Forty-six patients undergoing coronary artery bypass grafting or valve replacement were enrolled in this study. They were divided into three groups of drug administration. A bolus infusion of 50 mg/kg tranexamic acid was given to 17 patients at the end of cardiopulmonary bypass (control group) and to 14 patients at the beginning of cardiopulmonary bypass (group A). In addition to the same bolus infusion at the beginning of cardiopulmonary bypass as group A, a continuous infusion of 10 mg/kg per h, starting at the time of skin incision and maintained for 6 h after cardiopulmonary bypass was given to 15 patients (group B). The marked increase in α2-plasmin inhibitor—plasmin complexes at the end of cardiopulmonary bypass in the control group was significantly reduced in group A (P < 0.01) and a further reduction was observed in group B (P < 0.001). The difference in postoperative blood loss only reached significant levels between the control group and group B (P < 0.05). Although a significant increase in thrombin—antithrombin III complexes during cardiopulmonary bypass was similarly observed in all groups, no thromboembolic events occurred in any group, nor was any difference seen in graft patency. From the tranexamic acid therapy regimens tested in this study, a continuous infusion of 10 mg/kg per h starting at the time of skin incision to 6 h after cardiopulmonary bypass, with a bolus infusion of 50 mg/kg at the beginning of cardiopulmonary bypass, proved to be the most effective.

Original languageEnglish
Pages (from-to)195-199
Number of pages5
JournalVascular
Volume7
Issue number2
DOIs
Publication statusPublished - Jan 1 1999

Fingerprint

Tranexamic Acid
Antifibrinolytic Agents
Cardiopulmonary Bypass
Postoperative Hemorrhage
Fibrinolysin
Therapeutics
Control Groups
Skin
Hemostasis
Coronary Artery Bypass
Transplants

All Science Journal Classification (ASJC) codes

  • Surgery
  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Antifibrinolytic therapy with tranexamic acid in cardiac operations. / Matsuzaki, K.; Matsui, K.; Tanoue, Yoshihisa; Nagano, I.; Haraguchi, N.; Tatewaki, Hideki.

In: Vascular, Vol. 7, No. 2, 01.01.1999, p. 195-199.

Research output: Contribution to journalArticle

Matsuzaki, K. ; Matsui, K. ; Tanoue, Yoshihisa ; Nagano, I. ; Haraguchi, N. ; Tatewaki, Hideki. / Antifibrinolytic therapy with tranexamic acid in cardiac operations. In: Vascular. 1999 ; Vol. 7, No. 2. pp. 195-199.
@article{f9408cd8c0494944a34630d74982d5c4,
title = "Antifibrinolytic therapy with tranexamic acid in cardiac operations",
abstract = "To demonstrate its antifibrinolytic effects and establish an effective regimen of tranexamic acid for hemostasis, the authors measured α2-plasmin inhibitor—plasmin complexes, thrombin—antithrombin III complexes and postoperative blood loss in three groups undergoing different regimens during cardiac operations. Forty-six patients undergoing coronary artery bypass grafting or valve replacement were enrolled in this study. They were divided into three groups of drug administration. A bolus infusion of 50 mg/kg tranexamic acid was given to 17 patients at the end of cardiopulmonary bypass (control group) and to 14 patients at the beginning of cardiopulmonary bypass (group A). In addition to the same bolus infusion at the beginning of cardiopulmonary bypass as group A, a continuous infusion of 10 mg/kg per h, starting at the time of skin incision and maintained for 6 h after cardiopulmonary bypass was given to 15 patients (group B). The marked increase in α2-plasmin inhibitor—plasmin complexes at the end of cardiopulmonary bypass in the control group was significantly reduced in group A (P < 0.01) and a further reduction was observed in group B (P < 0.001). The difference in postoperative blood loss only reached significant levels between the control group and group B (P < 0.05). Although a significant increase in thrombin—antithrombin III complexes during cardiopulmonary bypass was similarly observed in all groups, no thromboembolic events occurred in any group, nor was any difference seen in graft patency. From the tranexamic acid therapy regimens tested in this study, a continuous infusion of 10 mg/kg per h starting at the time of skin incision to 6 h after cardiopulmonary bypass, with a bolus infusion of 50 mg/kg at the beginning of cardiopulmonary bypass, proved to be the most effective.",
author = "K. Matsuzaki and K. Matsui and Yoshihisa Tanoue and I. Nagano and N. Haraguchi and Hideki Tatewaki",
year = "1999",
month = "1",
day = "1",
doi = "10.1177/096721099900700209",
language = "English",
volume = "7",
pages = "195--199",
journal = "Vascular",
issn = "1708-5381",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Antifibrinolytic therapy with tranexamic acid in cardiac operations

AU - Matsuzaki, K.

AU - Matsui, K.

AU - Tanoue, Yoshihisa

AU - Nagano, I.

AU - Haraguchi, N.

AU - Tatewaki, Hideki

PY - 1999/1/1

Y1 - 1999/1/1

N2 - To demonstrate its antifibrinolytic effects and establish an effective regimen of tranexamic acid for hemostasis, the authors measured α2-plasmin inhibitor—plasmin complexes, thrombin—antithrombin III complexes and postoperative blood loss in three groups undergoing different regimens during cardiac operations. Forty-six patients undergoing coronary artery bypass grafting or valve replacement were enrolled in this study. They were divided into three groups of drug administration. A bolus infusion of 50 mg/kg tranexamic acid was given to 17 patients at the end of cardiopulmonary bypass (control group) and to 14 patients at the beginning of cardiopulmonary bypass (group A). In addition to the same bolus infusion at the beginning of cardiopulmonary bypass as group A, a continuous infusion of 10 mg/kg per h, starting at the time of skin incision and maintained for 6 h after cardiopulmonary bypass was given to 15 patients (group B). The marked increase in α2-plasmin inhibitor—plasmin complexes at the end of cardiopulmonary bypass in the control group was significantly reduced in group A (P < 0.01) and a further reduction was observed in group B (P < 0.001). The difference in postoperative blood loss only reached significant levels between the control group and group B (P < 0.05). Although a significant increase in thrombin—antithrombin III complexes during cardiopulmonary bypass was similarly observed in all groups, no thromboembolic events occurred in any group, nor was any difference seen in graft patency. From the tranexamic acid therapy regimens tested in this study, a continuous infusion of 10 mg/kg per h starting at the time of skin incision to 6 h after cardiopulmonary bypass, with a bolus infusion of 50 mg/kg at the beginning of cardiopulmonary bypass, proved to be the most effective.

AB - To demonstrate its antifibrinolytic effects and establish an effective regimen of tranexamic acid for hemostasis, the authors measured α2-plasmin inhibitor—plasmin complexes, thrombin—antithrombin III complexes and postoperative blood loss in three groups undergoing different regimens during cardiac operations. Forty-six patients undergoing coronary artery bypass grafting or valve replacement were enrolled in this study. They were divided into three groups of drug administration. A bolus infusion of 50 mg/kg tranexamic acid was given to 17 patients at the end of cardiopulmonary bypass (control group) and to 14 patients at the beginning of cardiopulmonary bypass (group A). In addition to the same bolus infusion at the beginning of cardiopulmonary bypass as group A, a continuous infusion of 10 mg/kg per h, starting at the time of skin incision and maintained for 6 h after cardiopulmonary bypass was given to 15 patients (group B). The marked increase in α2-plasmin inhibitor—plasmin complexes at the end of cardiopulmonary bypass in the control group was significantly reduced in group A (P < 0.01) and a further reduction was observed in group B (P < 0.001). The difference in postoperative blood loss only reached significant levels between the control group and group B (P < 0.05). Although a significant increase in thrombin—antithrombin III complexes during cardiopulmonary bypass was similarly observed in all groups, no thromboembolic events occurred in any group, nor was any difference seen in graft patency. From the tranexamic acid therapy regimens tested in this study, a continuous infusion of 10 mg/kg per h starting at the time of skin incision to 6 h after cardiopulmonary bypass, with a bolus infusion of 50 mg/kg at the beginning of cardiopulmonary bypass, proved to be the most effective.

UR - http://www.scopus.com/inward/record.url?scp=0032928727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032928727&partnerID=8YFLogxK

U2 - 10.1177/096721099900700209

DO - 10.1177/096721099900700209

M3 - Article

C2 - 10353670

AN - SCOPUS:0032928727

VL - 7

SP - 195

EP - 199

JO - Vascular

JF - Vascular

SN - 1708-5381

IS - 2

ER -